Product Details
| Product Name:
ST-1535 |
CAS No.:
496955-42-1 |
| Purity:
99.69% |
Supply Ability:
10g |
| Release date:
2026/05/11 |
Product Introduction
Bioactivity
| Name | ST-1535 |
| Description | ST 1535 is a potent and orally active antagonist of the A2A adenosine receptor, exhibiting antiparkinsonian activity and antitremorigenic effects, with potential for Parkinson's disease research. |
| In vitro | ST-1535 competitively antagonizes the effects of the A2A adenosine agonist NECA on cAMP in cells cloned with the human A2A adenosine receptor (IC50=353+/-30 nM), and the effects of the A1 adenosine agonist CHA on cAMP in cells cloned with the human A1 adenosine receptor (IC50=510+/-38 nM). [1] |
| In vivo | ST 1535, at oral doses of 5 and 10 mg/kg, antagonizes catalepsy induced by intracerebroventricular administration of the A2A adenosine agonist CGS 21680 (10 microg/5 microl) in mice. At oral doses ranging between 5 and 20 mg/kg, ST 1535 induces hypermotility and antagonizes haloperidol-induced catalepsy in mice up to 7 h. Oral ST 1535, at 1.25 and 2.5 mg/kg, potentiates L-dopa effects in reducing haloperidol-induced catalepsy. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (3.67 mM), Sonication is recommended.
DMSO : 9 mg/mL (33.05 mM), Sonication is recommended.
|
| Keywords | ST-1535 | ST1535 | ST 1535 | AdenosineReceptor | Adenosine Receptor | A2A |
| Inhibitors Related | Xanthine | Theophylline monohydrate | Diphylline | Adenosine monophosphate | Acefylline | Sulcatone | Adenosine 5'-monophosphate monohydrate | Inosine | Theobromine | Adenosine 5'-monophosphate disodium salt | Theophylline | Doxofylline |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1.00
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-07-05 |
|
|
$1980.00
|
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-21 |
|
|
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2026-06-30 |
United States